The company recorded $115.0 million from 46,011,900 warrants exercised between July 1, 2026 and the September 12, 2026 expiration date.

Cabaletta Bio’s warrants generated approximately $128.2 million in gross proceeds through their September 12, 2026 expiration, after 46,011,900 were exercised from July 1 through that date. Investors can distinguish the later exercise proceeds from the $13.2 million generated through June 30, 2026.

Key Highlights

  • Cabaletta Bio issued 53,090,190 common stock warrants in its June 2025 underwritten public offering.
  • Warrants exercised from July 1, 2026 through September 12, 2026 generated approximately $115.0 million in gross proceeds.
  • Aggregate gross proceeds from Warrant exercises through September 12, 2026 totaled approximately $128.2 million.

Cabaletta Bio, Inc. (NASDAQ: CABA) generated approximately $128.2 million in aggregate gross proceeds from common stock warrant exercises through the instruments’ September 12, 2026 expiration date. The warrants were issued in connection with the company’s June 2025 underwritten public offering.

Warrant Terms and Exercise Window

The warrant package consisted of 53,090,190 common stock warrants. Steven Nichtberger, Cabaletta Bio’s chief executive officer and president, signed on behalf of the company on September 14, 2026.

$115.0 Million Came After July 1

Cabaletta Bio reported 5,275,100 warrant exercises from issuance through June 30, 2026, producing approximately $13.2 million in aggregate gross proceeds. The company’s reported aggregate gross proceeds from warrant exercises across the period from issuance through expiration totaled approximately $128.2 million.